Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Silence Therapeutics Plc ADR (SLN)

Silence Therapeutics Plc ADR (SLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
New Strong Sell Stocks for May 9th Zacks - Tue May 9, 2023

ARCB, MRVL and SLN have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2023.

MRVL : 66.48 (-2.64%)
ARCB : 140.00 (-6.20%)
SLN : 21.56 (+1.46%)
Silence Therapeutics Achieves $10 Million Milestone Payment from AstraZeneca Collaboration Business Wire - Thu May 4, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics Completes Enrollment in Phase 2 Study of Zerlasiran (SLN360) in Subjects with Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events Business Wire - Mon May 1, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect Investor Conference Business Wire - Tue Apr 25, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics Announces Publication in Blood Demonstrating Role for Iron Regulation in Polycythemia Vera Business Wire - Tue Apr 4, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics to Present at Guggenheim’s Genomic Medicines and Rare Disease Days Business Wire - Wed Mar 29, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics Appoints Dr. Steven Romano as Incoming Chief Medical Officer and Head of Research and Development Business Wire - Tue Mar 28, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics to Buyback siRNA Complement Assets Business Wire - Tue Mar 28, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics Reports Fourth Quarter and Full Year 2022 Results Business Wire - Wed Mar 15, 2023

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through...

SLN : 21.56 (+1.46%)
Silence Therapeutics PLC Sponsored ADR (SLN) Stock Jumps 9.3%: Will It Continue to Soar? Zacks - Mon Mar 6, 2023

Silence Therapeutics PLC Sponsored ADR (SLN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving...

SLN : 21.56 (+1.46%)
OPTN : 1.0200 (-6.42%)

Barchart Exclusives

This Outperforming Dividend Aristocrat Could Rally Another 22%, Says Analyst Barchart - Wed Apr 17, 6:30PM CDT
With a track record of 30 years of dividend increases, this industrial stock is also delivering some outsized capital appreciation to shareholders lately. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot